Case report highlights treatment failure of MFM® therapy in thoracoabdominal aortic aneurysms, suggesting the need for further evaluation.
Thoracoabdominal aortic aneurysms (TAAAs) remain a major therapeutic challenge due to their anatomical extent and the need to preserve visceral perfusion. The Multilayer Flow Modulator (MFM®) is an endovascular alternative designed to modulate blood flow, promoting thrombosis within the aneurysm sac while maintaining patency of branch vessels. We report a case of treatment failure following MFM® implantation, leading to aneurysm progression, open surgical conversion, and death due to multiorgan failure.
No takes yet. Share an insight, caveat, or question.
Szponder et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: